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If imaging by physical methods is probably the best well-known link between physics
and medicine, other ways such as X-ray ﬂuorescence and diffraction techniques give
signiﬁcant information to clinicians. In this contribution, we would like to assess
different results obtained through such techniques on three main problems in urology
namely Randall's plaque, brushite kidney stones and phase conversion between wed-
dellite and whewellite. Randall's plaque is a mineral deposit at the surface of the renal
papilla which is responsible for the prevalence increase of kidney stones among young
people. X-ray ﬂuorescence suggests that an inﬂammation process is related to Randall's
plaque. X-ray ﬂuorescence shows that brushite stones, well known to be related to some
pathologies or biochemical disorders, could also be related to unexpected conditions as
suggested, for example, by the high content of Br found in several brushite stones. Such
results deserve further investigations to explain the origin of that element in the stones.
Regarding the phase conversion from weddellite to whewellite, X-ray ﬂuorescence data
suggest that trace elements initially present in the stone remain for the major part in
situ during the conversion process, which may be clinically relevant to relate the crys-
talline phase and etiology. X-ray ﬂuorescence and diffraction experiments can thus give
signiﬁcant clues to the clinicians. These examples as well as other investigations
assessed in this contribution underline a typical scientiﬁc transfer between a physics
laboratory and hospital.
© 2015 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since their discovery, X-ray related techniques have
gained wide acceptance in materials science. Among them,
X-ray ﬂuorescence (XRF) [1e4] and X-ray diffraction (XRD)
[5e8] are two well-established and powerful tools for a
non-destructive analysis of materials with broad applica-
tions in science and industry. In medicine, numerousouziere).
ed by Elsevier Masson SAS.investigations of biological entities have also been per-
formed with these techniques [9e15]. It is also possible to
combine both XRF and XRD on the same experimental set-
up to obtain simultaneously elemental and structural in-
formation on the sample. Furthermore, technical de-
velopments in X-ray laboratory sources, optics and
detectors in recent years have allowed performing mea-
surements at a local scale with micrometric X-ray beams
(~10 mm in diameter) to investigate possible heterogene-
ities. The fact that such measurements combining XRF and
XRD are now available in the laboratory offers a signiﬁcantThis is an open access article under the CC BY-NC-ND license (http://
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e1415 1405advantage, albeit the weaker X-ray intensity, over similar
experiments on synchrotron radiation facilities for which
experimental access is scarce. XRD and XRF techniques can
also be implemented at the hospital to help to characterize
pathologies or for disease diagnosis through in vivo ex-
periments [16].
In this contribution, wewould like to underline through
different kinds of XRF and XRD experiments, that chemical
and structural characteristics of pathological calciﬁcations
[17e19] give invaluable information to clinicians. For
example, most of the XRF experiments in medicine deal
with trace elements which are intrinsic components of
numerous biological systems, since a third of all known
proteins contain metal cofactors as catalytic components
[20]. Moreover, some trace elements are directly related to
a speciﬁc disease (aluminum to Alzheimer's disease [21];
copper accumulation toWilson disease [22]) or are present
in therapeutic drugs or diagnostic agents (cis-platin in
chemotherapy [23], gadolinium in magnetic resonance
imaging [24] as well different kinds of nanoparticles [25]).
After a brief description of the principles of XRF and XRD
techniques, we will present a set of experimental data
collected on such in-lab facilities.2. Basics of XRD and XRF techniques
2.1. Interaction of X-rays with matter
X-rays considered as an electromagnetic radiation
possess the duality of being both electromagnetic waves
with short wavelength l ranging typically from 0.1 to 1 Å
and massless non-charged particles named photons with
energies E from 1 to 100 keV. X-ray photons can interact
with the electrons in matter by three different mechanisms
as shown in Fig. 1: (i) the photo-electric effect when matter
absorbs the incident X-ray photon and then emits electrons
or X-ray photons, (ii) Compton scattering, where the scat-
tering of the incident X-ray photon is accompanied by some
energy transfer to the electron (inelastic scattering) and
(iii) Thomson (elastic) scattering where the scattered X-ray
photons have the same energy as in the incident beam.
Note that at low energy, the photoelectric effect is more
important than Compton scattering.Fig. 1. Schematic representation of the different interactions between X-rays
and matter.The photo-electric effect is responsible for the XRF and
Auger photoelectron phenomenawhereas XRD is related to
the Thomson scattering process. Note that photoelectron
spectroscopy is usually subdivided according to the source
of exciting radiation into X-ray Photoelectron Spectroscopy
(XPS) which uses soft X-rays (with a photon energy of
200e2000 eV) to examine core-levels and Ultraviolet
Photoelectron Spectroscopy (UPS) which is based on UV
radiation (with a photon energy of 10e45 eV) to examine
valence levels.2.2. X-ray ﬂuorescence
In the photoelectric absorption process, incident pho-
tons with quantum energy (hn) interact with an absorber
atom and completely disappear. In their place, photoelec-
trons are ejected from one of the bound shells of the atom
with energy equal to hnEb (where Eb represents the
binding energy of the photoelectron in its original shell, see
Fig. 2a). During the atomic relaxation, the ﬁlling of the
inner shell vacancy can produce X-ray ﬂuorescence radia-
tion with characteristic energies of the atom and also other
photoelectrons named Auger electrons [26,27].
The characteristic energies of the X-ray ﬂuorescence
radiation emitted from a sample enable us to identify
unambiguously and quantify the different elements pre-
sent. Such experiments can be performed on solid, liquid or
thin-ﬁlm samples. Finally, note that X-ray ﬂuorescence can
be also induced by gamma-emitting radioisotopes (241Am,Fig. 2. (a) Simple representation associated with the X-ray ﬂuorescence
process: 1 e incident X-ray photon, 2 e emitted photoelectron, 3 e X-ray
ﬂuorescence photon or 4 e Auger electron (b, c) schematic experimental set-
ups corresponding to (b) energy-dispersive (ED) and (c) wavelength-
dispersive (WD). For the ED experimental device, the energy resolution is
given by using the detector (around 150e200 eV) while for the WD one, the
energy resolution is deﬁned by using the monochromator (around 1e2 eV).
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e14151406109Cd, 153Gd, and others), protons [28e31], electron sources
and synchrotron light sources which produce highly
intense, coherent, monochromatic X-ray beams [32e36].
XRF can be in general measured with two types of
experimental set-ups: (i) energy-dispersive (ED-XRF) and
(ii) wavelength-dispersive (WD-XRF) spectrometers
(Fig. 2b). In the latter, the ﬂuorescence radiation is dif-
fracted by an analyzing single crystal optic just after the
sample to select with a high sensitivity a very narrow
wavelength or characteristic energy from an element of
interest in the sample. In the ED-XRF mode, the detector
allows us to detect simultaneously a broad range of char-
acteristic energies possibly related to several elements, the
selectivity depending on the energy resolution and count-
ing rate performance of the detector.
Laboratory X-ray sources must provide sufﬁciently high
energy radiation to be able to excite the characteristicFig. 3. (a) Picture of the in-lab EDXRF experimental set-up at LPS with monochrom
typical X-ray ﬂuorescence measured for a pathological calciﬁcation (a kidney stoneenergies of the broadest range of elements of the periodic
table; they are electric generators producing X-rays emis-
sion radiation from a high-Z element anode like molyb-
denum, silver or tungsten. X-ray optics, crystalline
monochromator or multilayer mirror is coupled with the
generator to deliver a focusing monochromatic beam onto
the sample that greatly improves the signal-to-noise ratio
for measurements of the characteristic energies of ele-
ments present in the sample (Fig. 3a).
In Fig. 3b, we can see clearly the contributions of Ar
(Ka ¼ 2958 eV), Ca (Ka ¼ 3691 eV, Kb ¼ 4012 eV), Fe
(Ka ¼ 6404 eV, Kb ¼ 7058 eV) and Zn (Ka ¼ 8638 eV,
Kb ¼ 9572 eV). Other contributions exist coming from in-
elastic process (Compton scattering) as well as the elastic
scattering related to the energy of the incident photons
generated by the molybdenum anode. Finally, the absence
of a signal at low energy (typical elements below Al) cannotatic X-ray MoKa radiation, the different elements are indicated by arrows (b)
). The contributions of trace elements such Fe and Zn are clearly visible.
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e1415 1407contribute to the spectrum due to air absorption, the high
difference between the incident energy of the MoKa and
the binding energy of the electrons of low Z elements
which induces a low probability of photoionization, and the
out-of-range (below 1 keV) sensitivity of the silicon drift
detector.
XRF is a representative multi-element technique for the
analysis of trace elements. This technique constitutes a
simple and rapid procedure of analysis for a large number
of samples, and has high sensitivity and low-detection
limits, enabling the determination of element concentra-
tions at trace levels.2.3. X-ray diffraction
At the atomic level, each atom of the sample deﬁnes a
scattered wave built from an incident X-ray beam. Wave-
lengths of X-rays being of the order of inter-atomic dis-
tances in the matter, the spatial periodic conﬁguration of
atoms causes phase interferences between scattered
waves, thus giving rise to the diffraction pattern. XRD was
discovered in 1913 by von Laue and by Bragg father and son
[37] who established the well-known Bragg formula, 2d
sin q ¼ n l (n is a positive integer), which connects the
wavelength l of the incident X-rays, the atomic lattice
interplanar distance d and the deviation angles q corre-
sponding to the constructive interferences of scattered
waves. From an experimental point of view, the XRDFig. 4. Schematic representation of the diffraction patterns on a plane de-
tector from a single crystal (a), a polycrystalline powder (b) and a prefer-
ential orientated powder (c).pattern is measured through a collection of diffraction
peaks at different Bragg angles 2q, their angular positions
and their intensities being intimately related to the spatial
arrangement of the atoms. In Fig. 4, the different cases of
diffraction from a single crystal (long range order periodic
atomic arrangement), a polycrystalline powder (random
orientation of small crystals) and a powder of crystallites
with a preferential orientation (texture) are shown to
illustrate the corresponding diffraction patterns.
XRD can bring different kinds of information on the
sample such as the identiﬁcation of the crystallographic
phases, its microstructure or its texture [38e41]. Generally,
XRD is used for phase identiﬁcation by comparing the
values of diffracted peaks with the ones tabulated in a data
base [42] and can also determine the structure of new
compounds. Recently, we have observed stone formation in
rats subjected to diets containing L-choline tartrate. Using
powder and single-crystal XRD, it is possible to determine
the crystallographic structure of completely new chemical
phase [43e45]. It is also possible to follow the formation
and reactivity of a phase or observing changes in lattice
constants under stress/change as, for example, to study
prosthesis under mechanical stress [46e50].2.4. In-lab micro-XRD and XRF
X-ray micro-diffraction (mXRD) is well adapted to
investigate the local variations of crystallographic proper-
ties such as the crystalline phase identiﬁcation, the
microstructure or the preferential orientation. It is also
valuable to combine such structural information with a
local elemental analysis by mXRF. The main concern to
perform experiments at a micrometric scale on a lab X-ray
source is to obtain an X-ray microbeam sufﬁciently intense.
Recent developments of instrumentation in X-ray optics
and detectors allow optimizing the detection of low-
intensity signals with a monochromatic CuKa X-ray
microbeamwith dimensions typically of 20 mm in diameter
[51]. In Fig. 5, the experimental setup includes a multilayer
mirror associated with a high-brilliance rotating-anode
generator delivering a well-deﬁned beam of sufﬁcient in-
tensity to measure mXRD and mXRF signals within a short
time (time scale from 1 to 10 min according to the sampleFig. 5. Picture of the in-lab mXRD/mXRF instrument at LPS with mono-
chromatic X-ray CuKa radiation, the different elements of the setup are
indicated.
Fig. 6. Randall's plaques observed at the mesoscopic scale. (a, b, and c) Randall's plaques made of calcium phosphate apatite (RP, red arrows) are positioned on
the kidney stone (KS, blue arrows) constituted of calcium oxalate monohydrate. Calcium phosphate apatite can be present within the tubular lumen (1 in b),
while other tubules are empty with calciﬁed walls (2 in b). In some cases (d), Randall's plaques are found at the surface of kidney stones made of calcium oxalate
dehydrate (KS, blue arrows).
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e14151408studied). Detectors using recently developed technology,
such as hybrid-pixel detectors are well suited to measure
the low-intensity signals. High-resolution motorized
translation stages allow performing area mapping studies
on materials.3. Randall's plaque, XRD and XRF
Crystallization may be induced in metastable supersat-
urated solutions by spontaneous nucleationwhen a certain
degree of supersaturation is reached (homogeneous
nucleation) or by an additional support made of seed
crystals or polymeric substances (heterogeneous nucle-
ation). One of the main challenges for urology in the 21st
century is related to a heterogeneous nucleation namely
the Randall's plaque (RP) [52e55]. These subepithelial
calciﬁcations of the renal papilla (Fig. 6) act as an anchor for
calcium oxalate monohydrate crystals and considerable
efforts have beenmade over the last decades to identify the
biochemical parameters responsible for this ectopic calci-
ﬁcation [56e65]. More precisely, a detailed description of
the interface area between a RP and a whewellite
(CaC2O4$H2O, calcium oxalate monohydrate, COM) stone at
the mesoscopic scale shows randomly distributed COM
crystals trapped in the carbonated apatite of RP [17]. S.C.
Kim et al. [66] have observed that stone formation is in fact
proportional to the papillary surface coverage by RP. It is
also worthwhile to note that such calciﬁcation of the renal
papilla may eventually become large enough to occlude the
tubular lumina and obliterate the tubular epithelium [67].This deposit is also present at the surface of kidney
stones [68,69]. In that case, even if other phosphate phases
such as whitlockite or brushite can be found as minor
components (less than 5%), calcium phosphate apatite (CA)
as well as amorphous carbonated calcium phosphate
(ACCP) are the major components of most RPs. In order to
improve our knowledge on the chemical composition of RP
present at the tip of the papilla, we use a technique speciﬁc
to synchrotron radiation namely, X-ray absorption spec-
troscopy [70,71]. Such a technique had already been used in
several investigations regarding pathological and physio-
logical calciﬁcations [72e76]. In the case of Randall's pla-
que, such experiments give for the ﬁrst time direct
structural evidence of the presence of ACCP as a major
constituent [77].
Based on these previous achievements, we have per-
formed XRD and XRF experiments on a set of RP extracted
using a stereomicroscope from seven human KSs and one
kidney stone made of calcium phosphate apatite (used in
this study as a reference compound) [78]. As it can be
observed in Fig. 7, XRD diagrams correspond to a relatively
ﬁne (002) diffraction peak (at 2q ¼ 26) and several poorly
resolved lines constituting a broad peak between 2q ¼ 30
and 2q ¼ 35. From these observations, it is quite easy to
conclude that RP are made of nanocrystalline particles
displaying the usual anisotropy along the c axis [79e84].
More interesting results have been collected by XRF
(Fig. 8). The contributions of different trace elements such
as Zn, Pb and Sr have been measured. These elements have
divalent cations and an ionic radius close to that of Ca2þ in
line with the Goldschmitt rules which are associated with
Fig. 7. X-ray diffraction diagrams collected with monochromatic copper
radiation (l ¼ 1.542 Å) for different RP and a KS made of apatite used as a
biological apatite reference sample in this study (after Ref. [78]). Measure-
ments were performed with an X-ray photosensitive image plate.
Fig. 8. Typical X-ray ﬂuorescence spectra collected for the RP and calibration
compound NIST610. For RP, we can clearly see the contributions of Ca
(EKa ¼ 3.691 keV, EKb ¼ 4.012 keV), Zn (EKa ¼ 8.638 keV, EKb ¼ 9.572 keV), Pb
(ELa ¼ 10.551 keV, ELb ¼ 12.613 keV) and Sr (Ea ¼ 14.165 keV,
EKb ¼ 15.835 keV) (after Ref. [78]). Measurements were performed with a
germanium detector.
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e1415 1409insertion processes [85]. Such data are in line with the fact
that apatitic calcium phosphates offer a wide range of ion
substitutions which can modify the physicalechemical and
biological properties of apatites [86e88]. The quantitative
analysis provides evidence that Zn levels are dramatically
increased in RP by comparison to the ones corresponding to
kidney stones of the same composition. The amount of Zn
(mg/g) is between 15 and 32 in kidney tissue, around 0.1 in
urine,1000 in CA kidney stones compared to 5600 in RP (up
to 10,000 in some cases) [78]. Such a high level of Zn sug-
gests that formation of calciﬁed deposits within the
medullar interstitium is clearly a pathological process
involving a tissue reaction in agreement with the decrease
of the kidney function [79e93].4. Hyperoxaluria, hypercalciuria and XRF
As reported for a long time, weddellite (CaC2O4$2H2O,
calcium oxalate dehydrate) is mainly related to hyper-
calciuria while whewellite is associated with hyperoxaluria
[94,95]. In a previous investigation [33], we have noticed
that Zn and Sr contents were higher inweddellite (290 mg/g
and 125 mg/g, respectively) than inwhewellite (42 mg/g and
61 mg/g, respectively) stones, suggesting signiﬁcant differ-
ences in the urine, including its content of Zn and Sr, which
is known to follow calcium pathways, seems to be
increased in kidney stones associated with hypercalciuricstates [33]. A simple question arises: what is the Zn content
in kidney stones made of whewellite for which a phase
conversion has occurred, considering that crystalline con-
version is observed for weddellite, which is able to trans-
form to whewellite. Crystalline conversion is suspected
when the morphological type of the stone is type II, typical
for the weddellite structure with large speciﬁc bipyramidal
crystals while the infrared spectrum clearly demonstrates
that whewellite is the main component of the corre-
sponding areas of the stone. By contrast, stones initially
made of whewellite exhibit a type I morphology, very
useful for assessing hyperoxaluric states as a driving force
of stone formation. In the case of crystalline conversion, the
initial stone morphology is preserved for a long time,
allowing easy detection of a conversion process by com-
parison between the morphology and composition of the
stone. Because crystalline conversion from weddellite to
whewellite implies a dissolution-crystallization process, it
was expected that all stones mainly composed of whe-
wellite, irrespective to the initial phase, should contain
signiﬁcantly less Zn and Sr than weddellite stones. To
answer this question, a new set of measurements have
been performed (Table 1). The ratio calculated from the
areas of the respective ﬂuorescence peaks of each element
allows us to carry out a semi-quantitative analysis to
compare the relative ratio of two elements in each sample.
As we can see, even if a large modulation of the Zn/Ca ratio
Table 1
Zn/Ca ratio obtained from calculated areas of the ﬂuorescence peaks of Ca (Kaþ Kb) and Zn (Ka) measured by XRF for different calcium oxalate kidney stones.
(Wh: whewellite; Wd: weddellite; CA: calcium phosphate apatite; Prot: proteins; WK: whitlockite). Note that ratio values are not molar quantity.
Stone reference Ca/Zn Ca/Sr Sex Morphological type of
the stone surface
Morphological type of
the stone section
Stone composition (number values
are indicated in %)
68,316 9.9 0.9 M IIb IIbþIVa Wh 60þCA 21þWd 15þProt 4
56,486 14.9 9.3 M IIaþIVa IIbþIVa Wd 44þCA 30þWh 20þProt 6
68,076 15.6 2.08 M IIb IIb Wh 52þWd 40þCA 5þBr 3
68,285 19.2 10 M IIb IIb Wd 56þWh 35þCA 7þProt 2
68,351 20.8 0.86 M IIbþIVa IIbþIVa Wd 36þCA 32þWh 28þProt 4
68,114 110 7.8 F IIbþIa IaþIIb Wh 50þWd 45þCA 3þProt 2
68,097 176 26 M IIbþId IaþIIb Wh 80þWd 11þCA 6þProt 3
57,503 230 10.8 M Ie Ie Wh 100
68,096 240 16.6 M Ia Ia Wh 100
68,231 261 30 F IIbþIVbþIa Ia Wh 36þWd 26þCA 25þWK 10þProt 3
68,074 272 23.9 M IaþIIb Ia Wh 65þWd 30þCA 3þProt 2
68,214 286 39 F Ia Ia Wh 100
8624 328 78 F Ia Ia Wh 100
68,140 380 7.9 M IaþIIb Ia Wh 64þWd 28þCA 4þProt 4
60,982 380 38 M Ie Ie Wh 100
68,102 410 30 F Ia Ia Wh 96þCA 2þProt 2
68,258 537 43 M Ia>IIb Ia Wh 80þWd 15þCA 3þProt 2
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measurements is able to distinguish between native whe-
wellite and whewellite coming fromweddellite as assessed
by the morphology of the stones. Studies based on XRF
conﬁrm our the ﬁrst results suggesting a different biolog-
ical environment for whewellite and weddellite crystalli-
zation, weddellite being associated with a Zn-rich
environment, partly favored by an inﬂammation process
[33,96]. Thus, whewellite resulting from weddellite con-
version by a dissolution-crystallization process (type-II
morphology) preserves the initial environment and pre-
sents a high content of Zn (and at a less extent strontium)
by comparison to native whewellite (type-I morphology).
The Ca/Zn and Ca/Sr ratios were, respectively, 16.1 ± 43.8
and 4.6 ± 7.5 for weddellite versus 300.8 ± 28.3 and
29.3 ± 4.9 for whewellite (p ¼ 0.000053 for Ca/Zn and
p¼ 0.015 for Ca/Sr). It could be of interest to assess the
relative ability of Zn and Sr adsorption and/or absorption
on weddellite and whewellite crystals in in vitro experi-
ments of synthesis of weddellite or whewellite crystals. As
observed in Table 1, the stone morphology compared with
the stone composition determined by infrared spectros-
copy helps us to identify crystalline conversion and thus
stone etiology.5. Brushite and X-ray ﬂuorescence
Brushite (dicalciumphosphatedihydrate, CaHPO4$2H2O),
named after the American mineralogist George Jarvis Brush
(1831e1912), [97] is a chemical compound which has a
pivotal role in medicine. Brushite as well as octacalcium
phosphate and amorphous calcium phosphate apatite have
been proposed as the earliest solid calcium phosphate phase
deposited inbone [98]. This isdue to the fact that if brushite is
more stable than hydroxyl-apatite in sufﬁciently acid solu-
tion, brushite hydrolyzes directly into hydroxyl-apatite at
sufﬁciently basic pH [99]. Brushite is also used in prosthesis
to improve the corrosion resistance and biocompatibility of
metallic alloys [100,101] or in cement implants for boneregeneration [102,103]. Finally, brushite can be identiﬁed in
different pathological calciﬁcations [104,105].
In urology, the main problem of brushite stones is their
resistance to fragmentation through extracorporeal
shockwave lithotripsy [106]. Through microcomputerized
tomography, it has been shown that resistance roughly
correlates with the stone density and increases with the
brushite mineral content, which is consistent with clinical
experience regarding patients with brushite calculi [107].
The fact that multiple lithotripsy sessions in a patient give
rise to the pathogenesis of brushite stones has also been
assessed [108,109].
D. Ackermann et al. [110] reported that the state of
saturation towards brushite was exclusively determined by
urinary calcium and pH, the latter below 5.5 showing a high
inﬂuence on brushite solubility. As underlined by C.Y. Pak
et al. [111], patients with predominantly brushite stones
could be distinguished from those with predominantly
hydroxyapatite and calcium oxalate stones by higher uri-
nary supersaturationwith respect to brushitemainly due to
hypercalciuria from absorptive hypercalciuria. Finally, R.
Siener et al. [112] noticed that hypercalciuria, a diminished
citrate excretion and an elevated pH turned out to be the
major urinary determinants of brushite stone formation.
Brushite is the most acidic form of calcium phosphates
identiﬁed in urine and stones. While carbapatite is a very
common component of urinary calculi, identiﬁed in various
proportions in about 85% of all stones, brushite is much less
frequent and is observed in less than 5% of urinary stones.
One explanation could be that brushite is considered an
instable phase of calcium phosphate which is able to
transform with time to carbapatite [113]. However, the
occurrence of brushite has been increasing for the past three
decades. In addition, the sex ratio (H/F) of patients pro-
ducing brushite stones is dramatically different from the
one obtained for patients producing carbapatite stones (the
ratio is 3.08 for brushite and 0.68 for carbapatite stones,
p < 0.00001). Finally, the strong relationship between
brushite and some pathological states or biochemical dis-
orders suggests that brushite could have a special place in
Fig. 9. FESEM photographs of brushite kidney stones. These observations show clearly that brushite kidney stones may display very different morphologies.
Unfortunately it was not possible to relate a speciﬁc morphology to a particular disease (i.e. primary hyperparathyroidism, hypercalciuria, mellitus diabetes, and
urinary tract infection). (f) Phase transition between brushite and apatite observed at a high magniﬁcation.
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strongly linked to hypercalciuric states (87% of patients
producing brushite stones exhibit hypercalciuria) [114].
Moreover, among well-deﬁned metabolic diseases, pri-
mary hyperparathyroidism is especially frequent in the
case of brushite stones (close to 20% of cases). Other causes
may be considered such as urinary tract infection, medul-
lary sponge kidney, phosphate leak, mellitus diabetes or
tubular acidiﬁcation defect. However, these pathological
conditions often induce mixed calcium phosphate stones
also containing high proportions of carbapatite. It seems
that multiple biochemical disorders such as poorly acidic
urine pH, high calcium, high phosphate and low citrate
concentration and/or excretion are required for brushite
stone formation [114].
Based on the well-established correlation between the
stone morphology and pathology [115e119] for COM [115]
and for some types of carbapatite stones [65], weexamined the brushite stone morphology and the content
of the main trace elements by comparisonwith the calcium
content. Four groups of brushite stones were selected ac-
cording to the pathology: primary hyperparathyroidism
(n¼ 8), hypercalciuria (n¼ 7), mellitus diabetes (n¼ 4) and
urinary tract infection (n ¼ 8). At the macroscopic and
mesoscopic scales, it was not possible to distinguish be-
tween all these pathologies from the stone morphology or
crystallite morphology assessed by SEM examination. To
illustrate this difﬁculty, the crystallite morphology through
a ﬁeld emission scanning electron microscope (FE-SEM)
implemented at the Laboratoire de Physique des Solides
(LPS) of brushite kidney stones is shown in Fig. 9.
Trace elements identiﬁed by X-ray ﬂuorescence (Figs. 10
and 11) were Br, Pb, Sr, Zn and Fe. The results were
expressed as the ratio of each element to the calcium
content (Table 2). Our data failed to ﬁnd any difference
between groups concerning the ratio Sr/Ca or Br/Ca. In
Fig. 10. X-ray ﬂuorescence spectra collected for brushite kidney stones
related to primary hyperparathyroidism (HPT). The X-ray ﬂuorescence
coming from Ar is due to the fact that measurements are performed under
ambient pressure.
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e14151412contrast, we observed that the Zn/Ca ratio was signiﬁcantly
higher in stones from diabetic patients in comparison to
hypercalciuria (0.0704 ± 0.0108 vs 0.0253 ± 0.008
(p < 0.01). These data suggest that other factors than
hypercalciuria (often present also in diabetic patients
because of a defect in calcium reabsorption) could explain
the high content in Zn. Especially, the inﬂammatory pro-
cess could be involved in those patients [120,121]. Of note,
the presence and sometimes the relatively high content of
Br in several brushite stones remains unexplained and
deserves further investigation.Fig. 11. X-ray ﬂuorescence spectra collected for brushite kidney stones
related to hypercalciuria.6. Toward in vivo XRF at the hospital
In the literature, numerous studies (Table 3) have
investigated the relationship between the content of trace
elements and different diseases [12,122e186] for different
kinds of biological samples. For example, L.M. Marco et al.
[130] and C.G.L. Canellas et al. [149] have determined the
Zn/Cu ratio in serum samples. D. von Czarnowski et al.
[127] have evaluated through total reﬂection X-ray ﬂuo-
rescence analysis the distribution of trace elements in
carcinomas of the digestive tract and in normal tissues of
human stomach, colon and rectum in correlation. Finally,
XRF offers the possibilities to determine the distribution of
Pt based anticancer drugswithin tumor and in its proximity
[126].
With the development of X-ray experimental setups
[12,124,133,135,165e186], some investigations have tried to
perform in vivo measurements of trace elements such as Fe
[185], Au [167], Zn [133,135], Cd [166,170], I [182], Hg
[171,179], Pu [186], U[174], Sr [178] and Pb [124,173]. As
underlined by several authors, such technique constitutes a
safe, rapid, and non-invasive approach. Some of these trace
elements namely Au [167] or I [182] are part of drugs or
biomedical markers. Gold salts are used in the treatment of
rheumatoid arthritis and such XRF experiments allow the
clinician to gather information on theirmode of action [167].
H. Matsukiyo et al. [182] have developed an XRF camera for
carryingoutmappingof iodine-based contrastmediaused in
medical angiography. In the case of excessive body toxic
element burdens, such as Pb [180], Hg [179] or Cd [166,170],
XRF measurements are a practical method for monitoring
the efﬁcacy of a therapy as well as for establishing the
diagnosis. In vivo XRF experiments have also been collected
on kidney [170]. As underlined by U. Nilsson et al. [170],
except in the presence of very deeply situated kidneys,
where the minimum detectable concentration is high, non-
invasive in vivo XRF analysis of kidney cadmium should be
a useful tool for evaluating the effects of long-term low-level
exposure to cadmium and the risk of kidney damage.
Quite recently, S.S. Shilstein et al. [133,135] described a
phantom-based feasibility investigation for a potential
in vivo determination of zinc in prostate. Such an approach
is based on several publications which have detailed the
compelling evidence and basis for the concept that zinc is
involved in the pathogenesis of prostate cancer and that
zinc could be efﬁcacious in the prevention and treatment of
this cancer [157e160]. Such measurements could bring
about improved diagnosis of prostate cancer which is the
most commonmalignancy affectingmen and is the second-
leading cause of cancer death [161].Table 2
Zn/Ca ratio obtained from the ﬂuorescence of Ca (Ka þ Kb) and Zn (Ka)
measured by XRF (counting acquisition of 20 min for each spectrum) for
different brushite kidney stones related to hyperparathyroidism, hyper-
calciuria, diabetes and urinary tract infections.
Disease Zn/Ca ratio
Primary hyperparathyroidism 0.0417 ± 0.0082
Hypercalciuria 0.0253 ± 0.008
Diabetes 0.0704 ± 0.0108
Infections 0.0423 ± 0.0078
Table 3
Biological tissues and diseases studied by XRF.
Biological
tissues
Etiology
Hair Environmental disease [129,151]
Brain Neurodegenerative diseases [131,134,142e144]
Breast Cancer [138]
Bone Relationship between Pb exposure and memory
impairment [124,141]
Cartilage Environmental disease [136], and Arthritis [137]
Gallstones Environmental [123]
Kidney
stones
Environmental [125]
Nails Environmental [129,145]
Prostate Cancer [135,139]
Serums Sickle cell anemia [149]
Skin Body iron burden [131] and Environmental [129]
Stomach Cancer [127]
Tooth
enamel
Environmental [129,142]
S. Rouziere et al. / C. R. Chimie 19 (2016) 1404e1415 1413Finally, L.H. Nie et al. [184] investigated the methodol-
ogy and feasibility of developing a portable X-ray ﬂuores-
cence (XRF) technology to quantify Pb in bone in vivo. The
authors report that with such a portable XRF device, the
detection limit was about 8.4 ppm with 2 mm soft tissue
thickness. Also, the entrance skin dose delivered to the
human subject was about 13 mSv and the total body
effective dose was about 1.5 mSv and that should pose
minimal radiation risk. They conclude that portable XRF
technology can be used for in vivo bone leadmeasurements
with sensitivity comparable to a standard technology.
Similar conclusions have beenmade byM. Estevam and C.R.
Appoloni [185] for the assessment of iron levels in patients
with thalassemia and hemochromatosis.
7. Conclusion and perspectives
Through these different examples, some of those being
already published, we have clearly demonstrated that in-
lab facilities bring signiﬁcant information to clinicians.
Such experimental devices allow the detection of trace el-
ements such Mg, Zn, Fe, Sr or Pb which play a major role in
medicine [187,188]. Their place in medical research will
increase drastically due to major public health problems
related to infection and environmental diseases. In the ﬁeld
of kidney stones, a new set of experiments will be dedi-
cated to assess through XRF the relationship between
infection and the content of Zn in the stones.
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